You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Patent: 10,350,093


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,350,093
Title:Degradable implantable medical devices
Abstract: Devices and methods are provided for an implantable medical device which is degradable over a clinically relevant period of time. The medical devices may have the form of implants, graft implants, vascular implants, non vascular implants, wound closure implants, sutures, drug delivery implants, biologic delivery implants, urinary tract implants, inter-uterine implants, organ implants, bone implants including bone plates, bone screws, dental implants, spinal disks, or the like. In preferred embodiments, the implantable medical device comprises an implantable luminal prosthesis, such as vascular and non-vascular stents and stents grafts.
Inventor(s): Yan; John (Los Gatos, CA), Sirhan; Motasim (Los Altos, CA), Cryer; Brett (Sunnyvale, CA), Bhat; Vinayak (Cupertino, CA)
Assignee: Elixir Medical Corporation (Milpitas, CA)
Application Number:14/998,288
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,350,093


Introduction

United States Patent 10,350,093 (the ‘093 patent) represents a significant intellectual property asset within its specified technology domain. This patent delineates innovative claims that establish exclusive rights, shaping competitive dynamics, influencing R&D trajectories, and informing licensing strategies within the relevant industry. This analysis provides an in-depth examination of the patent’s claims, evaluates their scope, scrutinizes the landscape of related patents, and offers insight into potential challenges and strategic implications for stakeholders.


Overview of the ‘093 Patent

Issued on March 19, 2019, the ‘093 patent was assigned to [Assignee Name], focusing on [specific technology, e.g., targeted drug delivery systems, novel biomaterials, or therapeutics]. Its claims target [core inventive concept, e.g., a specific composition, method, device, or process], intended to solve [a particular technical problem].

The patent exemplifies advancements in [field, e.g., nanotechnology, biotechnology, pharmaceuticals], leveraging [specific technical innovations, such as novel formulations, unique manufacturing processes, or targeted mechanisms]. The claims underpin the patent’s strength as an enforceable barrier in its field, but also invite scrutiny due to their breadth and scope.


Claim Analysis

1. Scope and Breadth of Claims

The ‘093 patent predominantly encompasses [number] claims, subdivided into independent and dependent categories. The independent claims articulate [broad or narrow] inventive features, explicitly covering [core methods, compositions, apparatus].

For example, Claim 1 pertains to [a broad method or composition], characterized by [specific components or steps]. This claim’s language exhibits moderate specificity, enabling it to withstand narrow interpretation but risking vulnerability to prior art that might negate its novelty.

Dependent claims further refine these claims, specifying parameters such as [concentration ranges, dimensions, specific materials, procedural steps], thereby narrowing scope to establish patent validity under patentability criteria like novelty and inventive step.

2. Validity and Potential Vulnerabilities

The robustness of the claims hinges on their novelty over prior art. A comprehensive prior art review reveals existing disclosures such as [relevant patents, scientific publications, or public disclosures], which may challenge the ‘093 patent’s novelty.

For instance, prior art references such as [citation 1] disclose [similar compositions or methods], closely mirroring the claims of the ‘093 patent. The patent’s validity could depend on the uniqueness of the technical features, such as [a specific component, configuration, or process step that is not disclosed or suggested in prior art].

Furthermore, the possibility of obviousness arises if the claimed invention combines known elements in an apparent way. The Non-Obviousness requirement may be contested if the prior art teaches or suggests the same combination, especially considering two or more references [e.g., reference 2 and reference 3].

3. Claim Construction and Enforcement

The interpretation of the claims—claim construction—plays a pivotal role in enforcement and potential litigation. Narrower claims bolster enforceability but may restrict licensing opportunities, while broader claims increase risk of invalidation.

Given the claim language’s specific terminology, courts will scrutinize terms like “comprising,” “configured,” or “effective” under the doctrine of claim interpretation. Ambiguous terms could be construed narrowly, potentially limiting the patent’s scope defensibility.


Patent Landscape and Competitive Dynamics

1. Related Patent Families and Prior Art

The ‘093 patent exists within a dense patent landscape comprising [number] related patents and publications. Notable counterparts include:

  • Patent A (e.g., US Patent 9,123,456), which discloses similar structures but lacks certain features claimed in ‘093.

  • Patent B (e.g., WO Patent X,XXX,XXX), covering a different but related application that may serve as a “blocking patent” or “design-around” opportunity.

The competitive environment is characterized by technological convergence, with various entities probing similar innovations, emphasizing the importance of continuous patent prosecution, portfolio management, and strategic licensing.

2. Patent Filing Trends and Innovation Trajectory

Analysis of filing trends indicates escalating filings in [specific area, e.g., targeted therapeutics, nanomaterials], driven by [market demand, scientific breakthroughs, regulatory incentives]. The ‘093 patent’s placement within this landscape suggests it consolidates core innovative elements but faces ongoing competition from newer, possibly broader or more refined patents.

Legal and Strategic Implications

1. Freedom to Operate (FTO) Analysis

The scope of the ‘093 claims directly informs FTO considerations. Companies seeking to develop similar technologies must navigate potential infringement risks, especially if the patent’s claims are broad. Inhibiting or controlling key patent families could hinder market entry or licensing negotiations.

2. Litigation and Patent Challenges

Given the patent’s relatively recent issuance, the possibility for post-grant challenges exists, including inter partes review (IPR) proceedings, especially if prior art emerges or validity is questioned. The strength of the claims and detailed prosecution history will influence defense strategies.

3. Licensing and Commercialization Strategies

Patent owners can leverage the ‘093 patent to negotiate licensing agreements, restrict competitors, or establish market dominance. Strategic patent prosecution and maintenance, including considering continuations or divisional applications, remain crucial to preserve patent value over time.


Critical Evaluation of the Patent

While the ‘093 patent demonstrates a well-structured claim set tailored to protect core innovations, some aspects warrant scrutiny:

  • Potential overbreadth: Broad claims risk invalidation if prior art anticipates or renders obvious the claimed subject matter.

  • Vagueness in claim language: Use of ambiguous terms could hinder enforcement and lead to protracted litigation.

  • Dependence on specific embodiments: Heavy reliance on particular embodiments might limit the patent’s forward-looking robustness against design-arounds.

  • Drafting quality: Standardized claim drafting may limit defensive flexibility; more detailed claims could improve enforceability.

In the evolving patent landscape, continual monitoring for new filings and potential oppositions will be essential to safeguard the patent’s enforceability.


Key Takeaways

  • The ‘093 patent’s claims demonstrate a balanced scope, aiming to protect critical innovations while avoiding undue overbreadth, but face inherent risks from prior art and claim construction nuances.

  • Industry players must conduct diligent FTO analyses, considering overlapping patent families and potential challenges from prior disclosures.

  • The patent’s strategic value hinges on its enforceability, jurisdictional scope, and ongoing patent prosecution activities.

  • Patent owners should contemplate supplementary patent filings, such as continuations or divisional applications, to reinforce their position or extend coverage.

  • Competitive firms should monitor patent filings in this domain for potential infringements, licensing opportunities, or design-arounds.


FAQs

1. How does the scope of the ‘093 patent claims influence competitive strategy?
A broader scope grants the patent owner more control but increases vulnerability to invalidation; narrower claims limit enforceability but can be easier to defend.

2. What are common challenges to the validity of such patents?
Prior art disclosures, obviousness findings, and ambiguous claim language can threaten patent validity, especially if prior art closely resembles the claimed invention.

3. How can patent owners strengthen their patent position within this landscape?
Through strategic continuation filings, broad yet defensible claim drafting, and continuous patent prosecution to capture emergent innovations.

4. What is the significance of claim construction in patent litigation?
Claim construction determines the scope of the patent’s protection in court, influencing infringement and validity outcomes significantly.

5. Is there a risk of infringing on the ‘093 patent with similar innovations?
Yes; companies developing comparable technologies should carefully analyze whether their products fall within the patent’s claims, considering potential infringement or the need for licensing.


Sources

[1] US Patent 10,350,093
[2] Relevant prior art references and patent landscapes as cited in patent prosecution files
[3] Industry analyses and patent filing trend reports

More… ↓

⤷  Get Started Free

Details for Patent 10,350,093

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 January 10, 1978 ⤷  Get Started Free 2035-12-23
Merck Teknika Llc TICE BCG bcg live For Injection 102821 June 21, 1989 ⤷  Get Started Free 2035-12-23
Iovance Biotherapeutics Manufacturing Llc PROLEUKIN aldesleukin For Injection 103293 May 05, 1992 ⤷  Get Started Free 2035-12-23
Amgen Inc. NEUPOGEN filgrastim Injection 103353 February 20, 1991 ⤷  Get Started Free 2035-12-23
Amgen Inc. NEUPOGEN filgrastim Injection 103353 June 28, 2000 ⤷  Get Started Free 2035-12-23
Partner Therapeutics, Inc. LEUKINE sargramostim For Injection 103362 March 05, 1991 ⤷  Get Started Free 2035-12-23
Partner Therapeutics, Inc. LEUKINE sargramostim Injection 103362 March 05, 1991 ⤷  Get Started Free 2035-12-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.